Organogenesis/$ORGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
869
ISIN
US68621F1021
Website
Organogenesis Metrics
BasicAdvanced
$415M
-
-$0.16
1.85
-
Price and volume
Market cap
$415M
Beta
1.85
52-week high
$6.71
52-week low
$2.28
Average daily volume
1.4M
Financial strength
Current ratio
4.122
Quick ratio
3.279
Long term debt to equity
9.068
Total debt to equity
11.583
Interest coverage (TTM)
5.04%
Profitability
EBITDA (TTM)
22.53
Gross margin (TTM)
75.85%
Net profit margin (TTM)
-3.46%
Operating margin (TTM)
1.13%
Effective tax rate (TTM)
34.50%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
0.70%
Return on equity (TTM)
-4.92%
Valuation
Price to revenue (TTM)
0.929
Price to book
1.71
Price to tangible book (TTM)
2.05
Price to free cash flow (TTM)
-60.852
Free cash flow yield (TTM)
-1.64%
Free cash flow per share (TTM)
-5.37%
Growth
Revenue change (TTM)
5.35%
Earnings per share change (TTM)
-493.73%
3-year revenue growth (CAGR)
-0.23%
3-year earnings per share growth (CAGR)
-36.96%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Bulls say / Bears say
Analysts have set a 12-month average price target of $5.50 for Organogenesis Holdings, indicating a potential upside of approximately 79.74% from the current stock price of $3.06. (stockanalysis.com)
The company is forecasted to grow earnings by 73.3% and revenue by 8.6% per annum, with EPS expected to grow by 72% annually, suggesting strong future financial performance. (simplywall.st)
Organogenesis Holdings has a debt-to-equity ratio of 0%, indicating a strong balance sheet with no debt obligations, which positions the company favorably for future growth. (simplywall.st)
The company reported a net loss of $15.17 million over the last 12 months, with a loss per share of $0.15, indicating ongoing profitability challenges. (stockanalysis.com)
Despite revenue growth, net profit has decreased for the last two quarters, with an average decrease of 37.8% per quarter, raising concerns about operational efficiency. (indmoney.com)
The stock price has increased by 32.47% in the last 52 weeks, but the beta of 1.85 suggests higher volatility compared to the market average, indicating potential risk for investors. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Organogenesis News
AllArticlesVideos
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness
GlobeNewsWire·2 months ago
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $415M as of June 20, 2025.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of June 20, 2025.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.